Qingbin Cui

Guangzhou Medical University

H指数:24

被引数:2,311

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Repurposing dimethyl fumarate for cancer therapy: current evidence and future directions

黄嘌呤二甲基酯的肿瘤治疗再利用：现有证据与未来方向

Frontiers in Pharmacology

IF4.8

2025-12-010

OAAI

Targeting Fatty Acid Synthase for Cancer Drug Discovery: Retrospective Analyses and Outlook

靶向脂肪酸合酶的抗癌药物发现：回顾性分析及展望

Pharmacological Reviews

IF17.3

2025-11-200

PRE

Investigation of the anticancer efficacy and impact on energy metabolism of dual-core gold(I) complex BGC2a

研究双核金(I)配合物BGC2a的抗肿瘤疗效及其对能量代谢的影响

RSC Med. Chem.

IF3.6

2025-08-220

PRE

Targeting fatty acid synthase to overcome PARP inhibitor resistance and to create an artificial synthetic lethality for triple-negative breast cancer

靶向脂肪酸合酶以克服PARP抑制剂耐药性并创造三阴性乳腺癌的人工合成致死效应

Genes & Diseases

IF9.4

2025-08-200

OAAI

Design, synthesis, and evaluation of quinoxaline-based survivin inhibitors for castration-resistant prostate cancer

基于喹喔啉的survivin抑制剂的 design, synthesis and evaluation for castration-resistant prostate cancer

Bioorganic Chemistry

IF4.7

2025-07-010

Gold complex QB1561 suppresses drug-resistant cancer cells by inhibiting TrxR and mitochondrial respiratory function

金配合物QB1561通过抑制硫氧还蛋白还原酶和线粒体呼吸功能来抑制耐药癌细胞。

FRONTIERS IN PHARMACOLOGY

IF4.8

2025-02-240

Novel gold-based complex GC7 suppresses cancer cell proliferation via impacting energy metabolism mediated by mitochondria

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2024-10-013

PRE

Small Molecule Inhibitors Targeting the Undruggable Survivin: The Past, Present, and Future from a Medicinal Chemist's Perspective

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2023-12-135

PRE

Synthesis and biological evaluation of novel bi-gold mitocans in lung cancer cells

FRONTIERS IN CHEMISTRY

IF4.2

2023-12-113

OAAI

A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells (vol 65, 116761, 2022)

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2023-01-010

PRE

Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-10-186

PRE

A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2022-07-0113

OAAI

Therapeutic implication of carbon monoxide in drug resistant cancers

BIOCHEMICAL PHARMACOLOGY

IF5.6

2022-07-0110

PRE

Editorial: Novel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers

FRONTIERS IN CHEMISTRY

IF4.2

2022-05-046

OAAI

Insights on the structure-function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies

MEDCOMM

IF10.7

2021-03-2512

OAAI

eIF3i regulation of protein synthesis, cell proliferation, cell cycle progression, and tumorigenesis

CANCER LETTERS

IF10.1

2021-03-0110

PREAI

Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance

DRUG RESISTANCE UPDATES

IF21.7

2021-01-01144

PREAI

Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter

FRONTIERS IN ONCOLOGY

IF3.3

2020-10-0927

OAAI

NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance

FRONTIERS IN ONCOLOGY

IF3.3

2020-07-2322

OAAI

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

FRONTIERS IN ONCOLOGY

IF3.3

2020-06-2540

OAAI

Qingbin Cui

个人简介

教育背景

工作经历

荣誉奖项

研究方向